Sign in
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Early Switch to the Dexamethasone Implant After Sub-Optimal Response to Anti-VEGF Therapy for Diabetic Macular Edema
Shawn Kavoussi, MD
2021
Real World Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Carl J Danzig, MD
Category: Diabetic Retinopathy